Taivex corporate with Development Center for Biotechnology (DCB), developed a first-in-class small molecule drug, T-1101. T-1101 is novel oral powder dosage Hec1/Nek2 inhibitor, which block the interaction of Hec1/Nek2 during tumor cell division and lead tumor cell apoptosis and achieve anti-cancer effect. Taivex licensed the lead compound of T-1101, a Hec1/Nek2 inhibitor「Tai-1」from Dr. Wen-Hwa Lee who is Academician, Academia Sinica.

Hec1/Nek2 is new anti-cancer target and this First-in-class new drug development challenge also brought T-1101 to received Honorable recognition at the MOEA (Ministry of Economic Affairs) 2011 Breakthrough Innovation of the Year Award.